The British trade publication Pharma Times describes the strategy of London lawyers representing the six patients in an ill-fated Phase I trial sponsored by TeGenero. That German sponsor had only $3.9 million in insurance on the trial, and the patients’ lawyers want more.

Because TeGenero declared itself bankrupt as the crisis erupted, the next target is Parexel, the American contract research organization (CRO) that hosted and ran the ill-fated trial. The Pharma Times article says the CRO is currently offering no settlement to the patients, citing the insurance money that remains unspent. While the lawyers say a general framework for a settlement could be finished within a month, to be followed by talks about specific patients, it’s not clear whether that agreement will include TeGenero, Parexel or both.

But lawyers retort that the men may face long-term disability and medical care, not to mention unpredictable deterioration as the years pass. Such care, they say, would quickly exhaust the $3.9 million. 

The Pharma Times story suggests that lawyers from Parexel are meeting with plaintiff lawyers and facing additional negative publicity about when steroids were administered to the patients and why the interval between dosages was so short.